Axogen
 | |
| Nasdaq: AXGN Russell 2000 Component | |
| Founded | 1 January 2002  |
| Headquarters | United States |
Axogen is a developer of surgical solutions, including human tissue grafts, based in Alachua, Florida.[1] Axogen products are designed to remedy peripheral nerve damage.[2][3][4] In 2013 the company raised $18 million in its initial public offering (IPO).[5] Axogen uses a cell graft technology AVANCE to mimic a human nerve. The company also creates nerve connectors and soft tissue membranes.[6] The company reports sensory and movement recovery in 87 percent of patients with peripheral nerve injuries. Axogen is part of the Sid Martin Biotechnology Incubator.
As of 2019, Axogen was the only commercially available allograft approved by the Food and Drug Administration (FDA) for clinical use.[citation needed]
See also
[edit]References
[edit]- ^ Inc, Axogen (2020-05-06). "Axogen, Inc. Reports First Quarter 2020 Financial Results". GlobeNewswire News Room. Retrieved 2020-06-03.
{{cite web}}:|last=has generic name (help) - ^ "Axogen, a peripheral". Medical Marketing & Media. Vol. 46, no. 2. London: Haymarket Media. February 2011. p. 17. Retrieved 22 June 2023 – via Gale General OneFile (Wikipedia Library).
- ^ Beck, Melinda (26 December 2012). "Graft Helps Nerves Regrow". The Wall Street Journal. Archived from the original on 4 March 2013.
- ^ Joseph, Drew (19 February 2013). "Nerve repair using grafts from cadavers". SFGATE. Retrieved 23 June 2023.
- ^ [Alachua] Business Briefs November 2013 Florida Trend Magazine
- ^ "Axogen Inc - Company Profile and News". www.bloomberg.com. Retrieved 2020-06-03.
 | This Florida-related article is a stub. You can help Wikipedia by expanding it. |